MedinCell is a clinical-stage pharmaceutical company developing long-acting injectables based on BEPO®, its game-changing technology platform enabling controlled, localized and sustained drug delivery. Independently and in partnership with other pharma or NGOs MedinCell develop a portfolio of best-in-class medicines incorporating additional benefits related to therapeutic compliance, targeted action, and ease of use.
BEPO® physicochemical properties make it an ideal vehicle for a broad variety of compounds such as peptides, proteins, and small molecules. BEPO® applications cover a wide range of unmet medical needs in neurology, cardiology, urology, gastroenterology, oncology, metabolic and immune diseases, pain management, and inflammation. In many situations, such as life cycle management, we can develop multiple.